XYLONOR

This brand name is authorized in Austria, Canada, Estonia, France, Hong Kong SAR China, Ireland, Malta, Romania, Singapore, Spain, UK.

Active ingredients

The drug XYLONOR contains a combination of these active pharmaceutical ingredients (APIs):

1	Lidocaine UNII 98PI200987 - LIDOCAINE
	Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.
	Read more about Lidocaine
2	Cetrimide UNII L64N7M9BWR - CETRIMONIUM BROMIDE
	Cetrimide is a quaternary ammonium cationic disinfectant with bactericidal activity against gram-positive and some gram-negative organisms. Cetrimide is relatively ineffective against viruses.
	Read more about Cetrimide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N01BB52	Lidocaine, combinations	N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides
Discover more medicines within N01BB52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	00479896, 02218607
EE	Ravimiamet	1125683
ES	Centro de información online de medicamentos de la AEMPS	50932, 51081
FR	Base de données publique des médicaments	60832521, 62835263, 66075758, 66081953
GB	Medicines & Healthcare Products Regulatory Agency	351302, 351316
HK	Department of Health Drug Office	43352
MT	Medicines Authority	MA035/00301, MA035/00302
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W03994001
SG	Health Sciences Authority	07224P